Multi-institutional atlas of brain metastases informs spatial modeling for precision imaging and personalized therapy

作者：Jorge Barrios, Evan Porter, Dante P. I. Capaldi, Taman Upadhaya, William Chen, Julian R. Perks, Aditya Apte, Michalis Aristophanous, Eve LoCastro, D. Hsu, Payton H. Stone, Javier Villanueva-Meyer, Gilmer Valdés, Fei Jiang, Michael Maddalena, Åse Ballangrud, Kayla Prezelski, Hui Lin, Jinger Sun, Muhtada A K Aldin, Oi Wai Chau, Benjamin Ziemer, Maasa Seaberg, Penny K. Sneed, Jean L. Nakamura, Lauren Boreta, Shannon Fogh, David R. Raleigh, Jessica Chew, Harish N. Vasudevan, Soonmee Cha, Christopher P. Hess, Rubén Fragoso, David Shultz, Luke Pike, Shawn L. Hervey‐Jumper, Derek S. Tsang, Philip V. Theodosopoulos, Daniel L. Cooke, Stanley Benedict, Ke Sheng, Jan Seuntjens, Catherine Coolens, Joseph O. Deasy, Steve Braunstein, Olivier Morin · 发表于：Nature Communications · 年份：2025 · DOI：10.1038/s41467-025-59584-7 · 被引用次数：9 · 研究领域：Medical Imaging Techniques and Applications、Brain Metastases and Treatment、Glioma Diagnosis and Treatment

Brain metastases are a frequent and debilitating manifestation of advanced cancer. Here, we collect and analyze neuroimaging of 3,065 cancer patients with 13,067 brain metastases, representing an extensive collection for research. We find that metastases predominantly localize to high perfusion areas near the grey-white matter junction, but also identify notable differences depending on the primary cancer histology as well as brain regions which do not conform to this relationship. Lung and breast cancers, in contrast to melanoma, frequently metastasize to the cerebellum, hinting at biological pathways of spread. Additionally, the deep brain structures are relatively spared from metastasis, regardless of primary cancer type. Leveraging this data, we propose a probabilistic brain metastasis risk model to enhance the therapeutic ratio of whole-brain radiotherapy by targeting high risk areas while preserving cortical and subcortical brain regions of functional significance and low metastasis risk, potentially reducing the cognitive side effects of therapy.